Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: A case series

References

• Assié MB, Ravailhe V, Faucillon V, Newman-Tancredi A. 2005. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 315:265–272.
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Gecici O. 2002. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: A single-blind, placebo-controlled study. Int Clin Psychopharmacol 17:115–119.
   PubMed Web of Science ®Google Scholar
• Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. 2006. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11:622–632.
   PubMed Web of Science ®Google Scholar
• Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, . 2005. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 315:1278–1287.
   PubMed Web of Science ®Google Scholar
• Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. 2004. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: A placebo-controlled trial. J Clin Psychiatry 65:565–568.
   PubMed Web of Science ®Google Scholar
• Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ. 2005. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: A double-blind, randomised, placebocontrolled study. BMC Psychiatry 5:5.
   PubMed Web of Science ®Google Scholar
• Chappell PB, Leckman JF, Riddle MA, Anderson GM, Listwack SJ, Ort SI, . 1992. Neuroendocrine and behavioral effects of naloxone in Tourette syndrome. Adv Neurol 58:253–262.
   PubMedGoogle Scholar
• Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR. 2005. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66:49–51.
   PubMed Web of Science ®Google Scholar
• Denys D, de Geus F, van Megen HJ, Westenberg HG. 2004. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65:1040–1048.
   PubMed Web of Science ®Google Scholar
• Endicott J, Spitzer RL, Fleiss JL, Cohen J. 1976. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33:766–771.
   PubMed Web of Science ®Google Scholar
• Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. 2005. Low-dose risperidone augmentation of fluvoxamine treatment in obsessivecompulsive disorder: A double-blind, placebo-controlled study. Eur Neuropsychopharmacol 15:69–74.
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Gale TM. 2005. Evidence-based pharmacotherapy of obsessive–compulsive disorder. Int J Neuropsychopharmacol 8:107–129.
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Stein DJ, Premkumar P, Carey P, Sivakumaran T, Vythilingum B, . 2006. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol 21:337–343.
   PubMed Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JB. 1996. Structured Clinical Interview for the DSM-IV Axis I Disorders. Washington: American Psychiatric Press.
   Google Scholar
• Fornaro M, Gabrielli F, Mattei C, Vinciguerra V, Fornaro P. 2008. Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report. Ann Gen Psychiatry 23:26.
   Google Scholar
• Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, . 1989. The Yale–Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46:1006–1011.
   PubMed Web of Science ®Google Scholar
• Hanssens L, L'Italien G, Loze JY, Marcus RN, Pans M, Kerselaers W. 2008. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 22:95.
   Google Scholar
• Hollander E, Kaplan A, Allen A, Cartwright C. 2000. Pharmacotherapy for obsessive–compulsive disorder. Psychiatr Clin North Am 23:643–656.
   PubMed Web of Science ®Google Scholar
• Insel TR, Pickar D. 1983. Naloxone administration in obsessive–compulsive disorder: report of two cases. Am J Psychiatry 140:1219–1220.
   PubMed Web of Science ®Google Scholar
• Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL. 1985. Obsessive–compulsive disorder and serotonin: is there a connection? Biol Psychiatry 20:1174–1188.
   PubMed Web of Science ®Google Scholar
• Jefferys D, Burrows G. 2008. Reversal of trichotillomania with aripiprazole. Depress Anxiety 25:E37–40.
   Google Scholar
• Kane J, Ingenito G, Ali M. 2000. Efficacy of Aripiprazole in psychotic disorder: comparison with haloperidol and placebo. Schizophr Res 41:39.
   Google Scholar
• Keuler DJ, Altemus M, Michelson D, Greenberg B, Murphy DL. 1996. Behavioral effects of naloxone infusion in obsessive–compulsive disorder. Biol Psychiatry 40:154–156.
   PubMed Web of Science ®Google Scholar
• Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, . 1999. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612–627.
   PubMed Web of Science ®Google Scholar
• Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, . 2010. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. Affect Disord 121(1–2):175–179.
   Google Scholar
• Matsubara K, Shimizu K, Suno M, Ogawa K, Awaya T, Yamada T, . 2006. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res 1112:126–133.
   PubMed Web of Science ®Google Scholar
• Matsunaga H, Hayashida K, Kiriike N, Maebayashi K, Stein DJ. 2009a. The clinical utility of symptom dimensions in obsessive-compulsive disorder. Psychiatry Res 180:25–29.
   Google Scholar
• Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ. 2009b. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 70:863–868.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. 1994. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51:302–308.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. 2000. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57:794–801.
   PubMed Web of Science ®Google Scholar
• Moran-Gates T, Massari C, Graulich A, Liégeois JF, Tarazi FI. 2006. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes. J Neurosci Res 84:675–682.
   Google Scholar
• Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, . 2002. International Treatment Refractory OCD Consortium, Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 5:181–191.
   PubMed Web of Science ®Google Scholar
• Pessina E, Albert U, Bogetto F, Maina G. 2009. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol 24:265–269.
   PubMed Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, . 1998. Acute and long-term efficacy and safety of aripiprazole: A new atypical antipsychotic. Schizophr Res 29:155.
   Google Scholar
• Saha AR, Petrie JL, Ali MW. 1999. Safety and efficacy profile of Aripiprazole, a novel antipsychotic. Schizophr Res 36:295.
   Google Scholar
• Sandyk R. 1987. Naloxone abolishes obsessive–compulsive behavior in Tourette's syndrome. Int J Neurosci 35:93–94.
   PubMed Web of Science ®Google Scholar
• Sarkar R, Klein J, Krüger S. 2008. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder. Psychopharmacology (Berlin) 197:687–688.
   PubMedGoogle Scholar
• Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK. 2004. A double-blind, placebocontrolled trial of olanzapine addition in fluoxetine-refractory obsessive compulsive disorder. Biol Psychiatry 55:553–555.
   PubMed Web of Science ®Google Scholar
• Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, . 2003. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400–1411.
   PubMed Web of Science ®Google Scholar
• Singh JB, Zarate CA Jr. 2006. Pharmacological treatment of psychiatric comorbidity in bipolar disorder: a review of controlled trials. Bipolar Disord 8:696–709.
   PubMed Web of Science ®Google Scholar
• Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, . 2007. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electro-physiological studies. Psychopharmacology (Berlin) 190:373–382.
   PubMed Web of Science ®Google Scholar
• Storch EA, Lehmkuhl H, Geffken GR, Touchton A, Murphy TK. 2008. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anxiety 25:172–174.
   Web of Science ®Google Scholar
• Stringfellow J, Ingenito G, Marder SR. 2003. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681–690.
   Google Scholar
• Tarazi FI, Zhang K, Baldessarini RJ. 2002. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berlin) 161:263–270.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Nisijima K, Katoh S, Yui K, Nakamura M. 2002. Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex. Neurochem Int 40:355–360.
   PubMed Web of Science ®Google Scholar
• Vulink NC, Denys D, Fluitman SB, Meinardi JC, Westenberg HG. 2009. Quetiapineaugments the effect of citalopram in non-refractory obsessive-compulsive disorder: A randomized, double-blind, placebocontrolled study of 76 patients. J Clin Psychiatry 70:1001–1008.
   PubMed Web of Science ®Google Scholar
• Zohar J, Zohar-Kadouch RC, Kindler S. 1992. Current concepts in the pharmacological treatment of obsessive–compulsive disorder. Drugs 43:210–218.
   Google Scholar
• Zohar J, Insel TR. 1987. Obsessive–compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology, Biol Psychiatry 22:667–687.
   PubMed Web of Science ®Google Scholar